⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL858847 | 0.70 | — | — | |
| SCHEMBL7899824 | 0.69 | — | — | |
| SCHEMBL532922 | 0.67 | — | — | |
| SCHEMBL7901818 | 0.61 | DYRK1A (0.33) | — | |
| SCHEMBL15935167 | 0.60 | — | — | |
| SCHEMBL3247768 | 0.60 | — | — | |
| SCHEMBL21672738 | 0.60 | — | — | |
| SCHEMBL2270501 | 0.55 | — | — | |
| SCHEMBL2646895 | 0.55 | — | — | |
| SCHEMBL8618825 | 0.55 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 200 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219465-A2 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme Inc (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-3498701-B1 | PRMT5 INHIBITORS AND USES THEREOF | EPIZYME INC (US) | 2023-02-22 | — | — | EP | disclosed |
| US-11185531-B2 | Arginine methyltransferase inhibitors and uses thereof | Epizyme, Inc. (US) | 2021-11-30 | — | — | US | disclosed |
| EP-3606926-B1 | HETEROAROMATIC COMPOUNDS USEFUL IN THERAPY | CUROVIR AB (SE) | 2021-05-26 | — | — | EP | disclosed |
| US-11001587-B2 | Substituted indazoles as phosphatidylinositol kinase inhibitors | CUROVIR AB (SE) | 2021-05-11 | — | — | US | disclosed |
| US-20210078951-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. | 2021-03-18 | — | — | US | disclosed |
| EP-2970132-B1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | EPIZYME INC (US) | 2020-09-23 | — | — | EP | disclosed |
| US-20200289469-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. | 2020-09-17 | — | — | US | disclosed |
| US-10632103-B2 | Arginine methyltransferase inhibitors and uses thereof | Epizyme, Inc. (US) | 2020-04-28 | — | — | US | disclosed |
| EP-3606926-A1 | HETEROAROMATIC COMPOUNDS USEFUL IN THERAPY | CUROVIR AB (SE) | 2020-02-12 | — | — | EP | disclosed |
| US-20050187219-A1 | Pyrazolotriazines as kinase inhibitors | SCHERING CORPORATION | 2005-08-25 | — | — | US | disclosed |
| US-20050059650-A1 | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. | 2005-03-17 | — | — | US | disclosed |
| WO-2005007658-A2 | FUSED-ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2005-01-27 | — | — | WO | disclosed |
| EP-1090005-B1 | PYRAZOLO 1,5-a]TRIAZINE CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2003-08-20 | — | — | EP | disclosed |
| EP-1090005-B1 | PYRAZOLO 1,5-a]TRIAZINE CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2003-08-20 | — | — | EP | disclosed |
| US-6509338-B1 | Psychiatric disorders and neurological diseases including affective disorder, anxiety, depression, headache, irritable bowel syndrome, post-traumatic stress disorder, supranuclear palsy, immune suppression, Alzheimer's disease, | BRISTOL-MYERS SQUIBB COMPANY | 2003-01-21 | — | — | US | disclosed |
| US-6509338-B1 | Psychiatric disorders and neurological diseases including affective disorder, anxiety, depression, headache, irritable bowel syndrome, post-traumatic stress disorder, supranuclear palsy, immune suppression, Alzheimer's disease, | BRISTOL-MYERS SQUIBB COMPANY | 2003-01-21 | — | — | US | disclosed |
| US-6509338-B1 | Psychiatric disorders and neurological diseases including affective disorder, anxiety, depression, headache, irritable bowel syndrome, post-traumatic stress disorder, supranuclear palsy, immune suppression, Alzheimer's disease, | BRISTOL-MYERS SQUIBB COMPANY | 2003-01-21 | — | — | US | disclosed |
| EP-1090005-A1 | PYRAZOLO 1,5-a]TRIAZINE CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | Du Pont Pharmaceuticals Company (US) | 2001-04-11 | — | — | EP | disclosed |
| WO-1999067247-A1 | PYRAZOLO[1,5-a]TRIAZINE CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | DU PONT PHARMACEUTICALS COMPANY (US) | 1999-12-29 | — | — | WO | disclosed |